Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
July 16, 2024 08:37 ET
|
Trethera Corporation
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Synthetic Immunology Market Report 2024 with Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
July 04, 2024 07:28 ET
|
Research and Markets
Dublin, July 04, 2024 (GLOBE NEWSWIRE) -- The "Synthetic Immunology Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Synthetic Immunology Market is...
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China
July 03, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Alumis Announces Pricing of Initial Public Offering
June 27, 2024 23:57 ET
|
Alumis Inc.
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
June 27, 2024 06:30 ET
|
Medigene AG
Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
June 21, 2024 04:30 ET
|
Medigene AG
Planegg/Martinsried, June 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
June 14, 2024 03:00 ET
|
Janssen Cilag International NV
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of...
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
June 03, 2024 11:00 ET
|
Biolojic Design
Biolojic Design Enters into Multi-Target Drug Discovery Collaboration
with Merck KGaA, Darmstadt, Germany in oncology and immunology
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...